{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:32:45Z","timestamp":1790843565500,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.hoc.2007.08.006","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T15:08:55Z","timestamp":1196953735000},"page":"1231-1246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Complications of Multiple Myeloma"],"prefix":"10.1016","volume":"21","author":[{"given":"Joan","family":"Blad\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2007.08.006_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","article-title":"Renal failure in multiple myeloma. Pathogenesis and prognostic implications","volume":"150","author":"Alexanian","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma. Presenting features and predictors of outcome in a series of 94 patients","volume":"158","author":"Blad\u00e9","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib3","series-title":"Myeloma: biology and management","first-page":"251","article-title":"Management of renal, hematologic, and infectious complications","author":"Blad\u00e9","year":"2004"},{"key":"10.1016\/j.hoc.2007.08.006_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0272-6386(83)80075-4","article-title":"Renal lesions in multiple myeloma: their relationship to associated protein abnormalities","volume":"4","author":"Hill","year":"1983","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hoc.2007.08.006_bib5","first-page":"484","article-title":"Pathogenesis and treatment of myeloma kidney","volume":"124","author":"Sanders","year":"1994","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib6","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.1990.00390160111022","article-title":"Treatment of renal failure associated to multiple myeloma","volume":"150","author":"Johnson","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM198203113061002","article-title":"\u201cIdiopathic\u201d Bence Jones proteinuria: long-term follow-up in seven patients","volume":"306","author":"Kyle","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2141.1995.tb05400.x","article-title":"Patients with multiple myeloma and renal failure requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases","volume":"91","author":"Torra","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib9","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","article-title":"Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 83 patients","volume":"12","author":"Blad\u00e9","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2007.08.006_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-9343(76)90440-X","article-title":"Manifestations of systemic light chain deposition","volume":"60","author":"Randall","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0889-8588(05)70417-2","article-title":"Biology and therapy of immunoglobulin deposition diseases","volume":"11","author":"Dhodapkar","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2007.08.006_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2003-10-3400","article-title":"Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma","volume":"104","author":"Ma","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2007.08.006_bib13","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/archinte.1982.00340250041008","article-title":"Reversible renal insufficiency in multiple myeloma","volume":"142","author":"Bernstein","year":"1982","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib14","first-page":"147","article-title":"Renal failure in multiple myeloma: a study of the presenting findings, response to treatment, and prognosis in 26 patients","volume":"28","author":"Cavo","year":"1986","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0002-9343(84)90781-2","article-title":"Acute renal failure in patients with multiple myeloma","volume":"76","author":"Cohen","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib16","first-page":"903","article-title":"Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment","volume":"270","author":"Iggo","year":"1989","journal-title":"Q J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0272-6386(12)81021-3","article-title":"The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma","volume":"6","author":"Korzets","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hoc.2007.08.006_bib18","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2007.08.006_bib19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplantation in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib20","first-page":"247","article-title":"Long-term survival in patients with acute and severe renal failure due to multiple myeloma","volume":"34","author":"Pasquali","year":"1990","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.hoc.2007.08.006_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0272-6386(87)80007-0","article-title":"Management of myeloma kidney: an anti-light-chain approach","volume":"10","author":"Misiani","year":"1987","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hoc.2007.08.006_bib22","first-page":"1","article-title":"Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: review of 50 cases","volume":"28","author":"Pozzi","year":"1987","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.hoc.2007.08.006_bib23","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure. A randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hoc.2007.08.006_bib25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.thj.6200115","article-title":"Initial treatment of multiple myeloma: long-term results in 914 patients","volume":"2","author":"Blad\u00e9","year":"2001","journal-title":"Hematol J"},{"key":"10.1016\/j.hoc.2007.08.006_bib26","unstructured":"Mecharchand J. Management of haematological complications of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, et al, editors. Myeloma: biology and management. 2nd edition. Oxford: Oxford University Press. p. 332\u201357."},{"key":"10.1016\/j.hoc.2007.08.006_bib27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2141.1992.tb06939.x","article-title":"Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production","volume":"82","author":"Berguin","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib28","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2002-06-1767","article-title":"Use of epoietin in patients with cancer: evidence-based clinical pactice guidelines of the American Society of Clinical Oncology and the American Society of Hematology","volume":"100","author":"Rizzo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2007.08.006_bib29","first-page":"40","article-title":"Use of epoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology","volume":"2","author":"Rizzo","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2007.08.006_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJM197910043011402","article-title":"The chemotherapy of plasma cell myeloma and the incidence of acute leukemia","volume":"301","author":"Bergsagel","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0308-2261(21)00329-5","article-title":"Plasma cell neoplasms and acute leukemia","volume":"11","author":"Bergsagel","year":"1982","journal-title":"Clin Haematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1034\/j.1600-0609.2000.90218.x","article-title":"Acute leukemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukemia Group study","volume":"65","author":"Finnish Leukemia Group","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1987.107","article-title":"A comparison of the incidence of myelodysplastic syndrome and acute leukemia following melphalan and cyclophosphamide treatment for multiple myeloma","volume":"55","author":"Cuzick","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2007.08.006_bib34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.1996.d01-1891.x","article-title":"Preceding standard therapy is the likely cause of MDS after autotransplants in multiple myeloma","volume":"95","author":"Govindarajan","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib35","series-title":"Myeloma","first-page":"223","article-title":"Infections: principle of prevention and therapy","author":"Kelleher","year":"2002"},{"key":"10.1016\/j.hoc.2007.08.006_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-96-1-47","article-title":"Biphasic pattern of bacterial infection in multiple myeloma","volume":"96","author":"Savage","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0002-9343(72)90010-1","article-title":"Current pattern of infection in multiple myeloma","volume":"52","author":"Meyers","year":"1972","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000225611","article-title":"Changing pattern of infection in patients with multiple myeloma","volume":"39","author":"Shaikh","year":"1982","journal-title":"Oncology"},{"key":"10.1016\/j.hoc.2007.08.006_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.hoc.2007.08.006_bib40","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","article-title":"Influence of treatment and response status on infection in multiple myeloma","volume":"71","author":"Perri","year":"1981","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(94)93028-7","article-title":"Frequency of infection in plateau-phase multiple myeloma","volume":"344","author":"Snowden","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2007.08.006_bib42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib43","first-page":"377","article-title":"Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicenter prospective survey","volume":"10","author":"Hoen","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hoc.2007.08.006_bib44","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM196712212772503","article-title":"Role of gammaglobulin for immunoprophylaxis in multiple myeloma","volume":"277","author":"Salmon","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib45","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.4049\/jimmunol.138.5.1464","article-title":"Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption","volume":"138","author":"Stashenko","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.hoc.2007.08.006_bib46","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V93.1.300","article-title":"Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"93","author":"Lacy","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2007.08.006_bib47","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0889-8588(05)70115-5","article-title":"The role of interleukin-1 beta in the pathogenesis of multiple myeloma","volume":"13","author":"Lust","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2007.08.006_bib48","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","article-title":"Interleukin-6 in human multiple myeloma","volume":"85","author":"Klein","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2007.08.006_bib49","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.hoc.2007.08.006_bib50","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2007.08.006_bib51","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2007.08.006_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib54","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blinded, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.hoc.2007.08.006_bib55","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2007.08.006_bib56","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hoc.2007.08.006_bib57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib58","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2007.08.006_bib59","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2007.08.006_bib60","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2007.08.006_bib61","series-title":"Myeloma: biology and management","first-page":"269","article-title":"Neurological manifestations of myeloma and their management","author":"Gawler","year":"2004"},{"key":"10.1016\/j.hoc.2007.08.006_bib62","series-title":"Cancer and nervous system. The neurological manifestations of systemic malignant disease","author":"Henson","year":"1982"},{"key":"10.1016\/j.hoc.2007.08.006_bib63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30865-3","article-title":"Back pain and epidural spinal cord compression","volume":"71","author":"Posner","year":"1987","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.hoc.2007.08.006_bib64","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/1097-0142(19820415)49:8<1710::AID-CNCR2820490829>3.0.CO;2-H","article-title":"Multiple nerve palsies as the presenting feature of meningeal myelomatosis","volume":"49","author":"Woodruff","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2007.08.006_bib65","series-title":"Handbook of clinical neurology","first-page":"131","article-title":"Paraproteinemias and multiple myeloma","author":"Spaar","year":"1980"},{"key":"10.1016\/j.hoc.2007.08.006_bib66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/10428190310001597964","article-title":"Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features","volume":"45","author":"Fassas","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2007.08.006_bib67","first-page":"301","article-title":"Peripheral neuropathy associated to antiMAG antibodies","volume":"3","author":"Latov","year":"1988","journal-title":"Crit Rev Neurobiol"},{"key":"10.1016\/j.hoc.2007.08.006_bib68","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long term prognosis of neuropathy associated with antiMAG IgM M-proteins and its relationship to immune therapies","volume":"123","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2007.08.006_bib69","first-page":"a551","article-title":"Therapy of neuropathy associated with antiMAG IgM monoclonal gammopathy with Rituxan","volume":"52","author":"Latov","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.hoc.2007.08.006_bib70","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody related polyneuropathies: B-cell depletion chemotherapy using rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.hoc.2007.08.006_bib71","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2783.x","article-title":"Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration","volume":"77","author":"Cibeira","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2007.08.006_bib72","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858807001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858807001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:51:28Z","timestamp":1760183488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858807001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0889858807001141"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2007.08.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2007.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}